Literature DB >> 15963099

Queen Mary Utilization of Antihypertensive Drugs Study: use of antihypertensive drug classes in the hypertension clinic 1996-2004.

Bernard M Y Cheung1, Yuk Lin Wong, Chu Pak Lau.   

Abstract

BACKGROUND: Utilization of antihypertensive drugs in the hypertension outpatient clinic is surveyed periodically in the Queen Mary Utilization of Antihypertensive Drugs Study (QUADS).
METHODS: Two hundred and fifty-one patients (123 men, 128 women) were interviewed in April to December 1996, 439 patients (232 men, 207 women) in January to December 99 and 228 patients (109 men, 119 women) in April to May 2004. Their case notes were reviewed.
RESULTS: The percentages of patients receiving no drug (lifestyle modification), one, two, three and over three drugs were 7%, 48%, 36%, 7%, 3%, respectively, in 1996; 14%, 34%, 36%, 13% and 1%, respectively, in 1999; and 3%, 30%, 40%, 22% and 6%, respectively, in 2004. The number of drugs correlated with age and overweight. In 1996, 51% patients received calcium channel blockers (CCB); 46% beta-blockers (BB); 32% angiotensin-converting enzyme inhibitors (ACEI); 15% thiazide diuretics; 5% alpha-blockers; and 0% angiotensin receptor blockers (ARB). In 1999, the respective figures were 52% CCB, 49% BB, 24% ACEI, 22% thiazide diuretics, 4%alpha-blockers and 2% ARB. In 2004, the respective figures were 65% CCB, 64% BB, 33% ACEI, 24% thiazide diuretics, 4% alpha-blockers and 7% ARB. Fewer patients on BBs reported side-effects. Only 11% were on alpha statin and 9% on aspirin. Blood pressure on treatment was 147 +/- 21/84 +/- 11 mmHg in 1999 and 144 +/- 21/82 +/- 11 mmHg in 2004.
CONCLUSIONS: Increasingly, multiple drugs were used for blood pressure control. Blood pressure control needs improvement, especially in diabetics. CCBs and BBs were consistently popular. Thiazide diuretics, ARBs, statins and aspirin were underused, despite favourable clinical trial evidence.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15963099      PMCID: PMC1884897          DOI: 10.1111/j.1365-2125.2005.02388.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  30 in total

1.  Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group.

Authors:  J M Lazarus; J J Bourgoignie; V M Buckalew; T Greene; A S Levey; N C Milas; L Paranandi; J C Peterson; J G Porush; S Rauch; J M Soucie; C Stollar
Journal:  Hypertension       Date:  1997-02       Impact factor: 10.190

2.  Racial difference in incidence of cough with angiotensin-converting enzyme inhibitors (a tale of two cities).

Authors:  K S Woo; R M Norris; G Nicholls
Journal:  Am J Cardiol       Date:  1995-05-01       Impact factor: 2.778

3.  The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V)

Authors: 
Journal:  Arch Intern Med       Date:  1993-01-25

4.  2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension.

Authors:  Judith A Whitworth
Journal:  J Hypertens       Date:  2003-11       Impact factor: 4.844

5.  Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV.

Authors:  B Williams; N R Poulter; M J Brown; M Davis; G T McInnes; J F Potter; P S Sever; S McG Thom
Journal:  J Hum Hypertens       Date:  2004-03       Impact factor: 3.012

6.  Relative efficacy and tolerability of lacidipine and amlodipine in patients with mild-to-moderate hypertension: a randomized double-blind study.

Authors:  C P Lau; B M Cheung
Journal:  J Cardiovasc Pharmacol       Date:  1996-08       Impact factor: 3.105

7.  Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000.

Authors:  Ihab Hajjar; Theodore A Kotchen
Journal:  JAMA       Date:  2003-07-09       Impact factor: 56.272

8.  2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension.

Authors: 
Journal:  J Hypertens       Date:  2003-06       Impact factor: 4.844

9.  Prescription patterns of hypertension--National Health Insurance in Taiwan.

Authors:  Chih-Chieh Chou; Meei-Shynan Lee; Ching-Hsing Ke; Mieng-Hsian Chung
Journal:  J Chin Med Assoc       Date:  2004-03       Impact factor: 2.743

10.  Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002.

Authors:  Randall S Stafford; Curt D Furberg; Stan N Finkelstein; Iain M Cockburn; Tseday Alehegn; Jun Ma
Journal:  JAMA       Date:  2004-01-07       Impact factor: 56.272

View more
  3 in total

1.  Changes in the usage of antihypertensive drugs: implications and prospects.

Authors:  Mike Schachter
Journal:  Br J Clin Pharmacol       Date:  2005-09       Impact factor: 4.335

2.  How does prescribing for antihypertensive products stack up against guideline recommendations? An Australian population-based study (2006-2014).

Authors:  Andrea L Schaffer; Sallie-Anne Pearson; Nicholas A Buckley
Journal:  Br J Clin Pharmacol       Date:  2016-07-28       Impact factor: 4.335

3.  Individuals at risk of beta-blocker discontinuation: a cohort study in 19,177 Chinese patients.

Authors:  Martin C S Wong; Johnny Y Jiang; Xuefen Su; Haoxiang Wang; Jin Ling Tang; Sian M Griffiths
Journal:  Clin Res Cardiol       Date:  2010-02-21       Impact factor: 5.460

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.